(NOVT) Novanta - Overview
Stock: Lasers, Encoders, Motors, Pumps, Vision
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.3% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -27.57 |
| Character TTM | |
|---|---|
| Beta | 1.604 |
| Beta Downside | 1.580 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.71% |
| CAGR/Max DD | -0.09 |
Description: NOVT Novanta January 08, 2026
Novanta Inc. (NASDAQ: NOVT) operates two primary segments: Automation Enabling Technologies, which supplies laser-based components, precision motors, encoders and robotic end-of-arm solutions for advanced manufacturing and medical robotics; and Medical Solutions, which offers medical-grade devices such as insufflators, pumps, laser delivery systems, machine-vision and RFID technologies. The company markets its products through a mix of direct sales and a broad distributor network under brands including Cambridge Technology, Synrad, Laser Quantum, and ThingMagic. Formerly GSI Group, Novanta has been publicly listed under its current name since 2016 and is headquartered in Bedford, Massachusetts.
Key recent metrics indicate the firm generated roughly $1.1 billion in revenue for FY 2023, with an operating margin near 14% and a 5-year compound annual growth rate (CAGR) of ~6% in the automation segment-driven by rising capital expenditures in semiconductor fab equipment and the adoption of laser-based manufacturing in electric-vehicle battery production. On the medical side, demand for ophthalmic lasers and minimally invasive surgical tools is supported by an aging population and increasing outpatient procedure volumes, both of which have historically contributed a 3-4% revenue uplift year-over-year for companies in the G-GICS “Health Care Equipment & Supplies” sub-industry.
For a deeper quantitative view, you might explore the ValueRay platform’s detailed financial models for NOVT.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 52.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.28 > 1.0 |
| NWC/Revenue: 29.32% < 20% (prev 30.38%; Δ -1.06% < -1%) |
| CFO/TA 0.08 > 3% & CFO 116.8m > Net Income 52.8m |
| Net Debt (416.1m) to EBITDA (171.5m): 2.43 < 3 |
| Current Ratio: 2.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.0m) vs 12m ago -0.25% < -2% |
| Gross Margin: 44.80% > 18% (prev 0.44%; Δ 4436 % > 0.5%) |
| Asset Turnover: 65.67% > 50% (prev 65.04%; Δ 0.63% > 0%) |
| Interest Coverage Ratio: 4.61 > 6 (EBITDA TTM 171.5m / Interest Expense TTM 24.4m) |
Altman Z'' 3.48
| A: 0.19 (Total Current Assets 468.4m - Total Current Liabilities 186.9m) / Total Assets 1.51b |
| B: 0.20 (Retained Earnings 303.9m / Total Assets 1.51b) |
| C: 0.08 (EBIT TTM 112.3m / Avg Total Assets 1.46b) |
| D: 1.03 (Book Value of Equity 725.0m / Total Liabilities 704.3m) |
| Altman-Z'' Score: 3.48 = A |
Beneish M -3.05
| DSRI: 1.00 (Receivables 170.6m/164.5m, Revenue 960.3m/922.8m) |
| GMI: 0.99 (GM 44.80% / 44.42%) |
| AQI: 1.01 (AQ_t 0.58 / AQ_t-1 0.58) |
| SGI: 1.04 (Revenue 960.3m / 922.8m) |
| TATA: -0.04 (NI 52.8m - CFO 116.8m) / TA 1.51b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of NOVT shares?
Over the past week, the price has changed by +5.15%, over one month by +13.46%, over three months by +31.89% and over the past year by -4.80%.
Is NOVT a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NOVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 154 | 8.9% |
| Analysts Target Price | 154 | 8.9% |
| ValueRay Target Price | 131.8 | -6.9% |
NOVT Fundamental Data Overview February 05, 2026
P/S = 5.1238
P/B = 6.1027
P/EG = 2.11
Revenue TTM = 960.3m USD
EBIT TTM = 112.3m USD
EBITDA TTM = 171.5m USD
Long Term Debt = 445.7m USD (from longTermDebt, last quarter)
Short Term Debt = 16.7m USD (from shortTermDebt, last quarter)
Debt = 505.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 416.1m USD (from netDebt column, last quarter)
Enterprise Value = 5.34b USD (4.92b + Debt 505.3m - CCE 89.2m)
Interest Coverage Ratio = 4.61 (Ebit TTM 112.3m / Interest Expense TTM 24.4m)
EV/FCF = 52.01x (Enterprise Value 5.34b / FCF TTM 102.6m)
FCF Yield = 1.92% (FCF TTM 102.6m / Enterprise Value 5.34b)
FCF Margin = 10.68% (FCF TTM 102.6m / Revenue TTM 960.3m)
Net Margin = 5.50% (Net Income TTM 52.8m / Revenue TTM 960.3m)
Gross Margin = 44.80% ((Revenue TTM 960.3m - Cost of Revenue TTM 530.1m) / Revenue TTM)
Gross Margin QoQ = 44.76% (prev 44.28%)
Tobins Q-Ratio = 3.54 (Enterprise Value 5.34b / Total Assets 1.51b)
Interest Expense / Debt = 1.19% (Interest Expense 6.01m / Debt 505.3m)
Taxrate = 32.40% (5.11m / 15.8m)
NOPAT = 75.9m (EBIT 112.3m * (1 - 32.40%))
Current Ratio = 2.51 (Total Current Assets 468.4m / Total Current Liabilities 186.9m)
Debt / Equity = 0.63 (Debt 505.3m / totalStockholderEquity, last quarter 801.5m)
Debt / EBITDA = 2.43 (Net Debt 416.1m / EBITDA 171.5m)
Debt / FCF = 4.05 (Net Debt 416.1m / FCF TTM 102.6m)
Total Stockholder Equity = 779.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.61% (Net Income 52.8m / Total Assets 1.51b)
RoE = 6.78% (Net Income TTM 52.8m / Total Stockholder Equity 779.6m)
RoCE = 9.17% (EBIT 112.3m / Capital Employed (Equity 779.6m + L.T.Debt 445.7m))
RoIC = 6.28% (NOPAT 75.9m / Invested Capital 1.21b)
WACC = 10.80% (E(4.92b)/V(5.43b) * Re(11.83%) + D(505.3m)/V(5.43b) * Rd(1.19%) * (1-Tc(0.32)))
Discount Rate = 11.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.05%
[DCF Debug] Terminal Value 72.71% ; FCFF base≈107.5m ; Y1≈132.6m ; Y5≈225.8m
Fair Price DCF = 56.05 (EV 2.42b - Net Debt 416.1m = Equity 2.01b / Shares 35.8m; r=10.80% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -40.89 | EPS CAGR: -46.81% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.46 | Revenue CAGR: 6.03% | SUE: 0.97 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.83 | Chg30d=-0.015 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=3.61 | Chg30d=-0.040 | Revisions Net=-1 | Growth EPS=+11.1% | Growth Revenue=+6.7%